It looks like you’ve shared an excerpt discussing the advancements and challenges in cell and gene therapies (CGTs) based on McKesson’s 2026 Cell and Gene Therapy Report. Here are some key points summarized from that content:
Key Takeaways
-
Advancement in CGTs:
- CGTs, once thought impossible, are having a significant real-world impact.
- There’s an ongoing need to expedite patient access to these therapies alongside scientific progress.
-
Focus of the 2026 Report:
- The report includes insights from various stakeholders—providers, payers, manufacturers, and patients.
- It highlights new areas of growth, particularly in autoimmune diseases and ophthalmology.
-
Clinical Trial Mapping:
- This year, the report presents a mapping of CGT clinical trial activities across the U.S.
- A small number of sites dominate trial activities, revealing concentrated expertise in the field.
-
AI Potential:
- The introduction of AI-driven tools is seen as promising in bridging gaps in patient access to therapies.
- Experts believe AI could significantly increase the number of eligible patients receiving CAR-T therapies.
-
Future Directions:
- The focus is not only on bringing more therapies to market but on ensuring they reach patients effectively.
The full details and further insights can be explored in InspiroGene by McKesson’s interactive map and report.
